We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02632851
Recruitment Status : Completed
First Posted : December 17, 2015
Last Update Posted : June 21, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This observational, non-interventional multicentric study compares the inhalation therapy on patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin inhalation solution and Pari NaCl (0.9%) inhalation solution

Condition or disease
Bronchitis Cough Sputum, Cellular Atypia Dyspnoea

Detailed Description:
The assessment focuses on the bronchitis Severity Score (BSS) for standardized use in clinical studies with the outcome criteria of cough, sputum production, rales/rhonchi, chest pain during coughing and dysnoea

Study Design

Study Type : Observational
Actual Enrollment : 135 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Non-interventional Multicentric Study on Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
Study Start Date : December 2015
Primary Completion Date : May 2016
Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acute Bronchitis
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Ectoin inhalation solution
treatment according to instructions for use
Pari NaCl inhalation solution (0.9%)
treatment according to instructions for use


Outcome Measures

Primary Outcome Measures :
  1. Change in Bronchitis Severity Score on physician´s evaluation (5 point IMOS scale) [ Time Frame: day 7 ]

    Assessment of bronchits severity score on a 5 point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration) of symptoms:

    Cough, sputum production, rales/rhonchi, chest pain during coughing, dyspnoea



Secondary Outcome Measures :
  1. Change in bronchitis symptoms evaluated on patients´ diaries (5 point scale) [ Time Frame: day 14 ]

    Assessment of bronchits symptoms on a 5 point scale (absent, mild, moderate, severe, very severe) of symptoms:

    Cough, sputum production, rales/rhonchi, chest pain during coughing, dyspnoea


  2. patients´ evaluation of tolerability (4 point scale) [ Time Frame: day7 ]
    assessment of tolerability on a 4 point scale (bad, satisfied, good, very good)

  3. physicians´ evaluation of tolerability (4 point scale) [ Time Frame: day 7 ]
    assessment of tolerability on a 4 point scale (bad, satisfied, good, very good)

  4. patients´ evaluation of efficacy (five point IMOS scale) [ Time Frame: day 7 ]
    assessment of tolerability on a five point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration)

  5. physicians´ evaluation of efficacy (five point IMOS scale) [ Time Frame: day 7 ]
    assessment of tolerability on a five point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration)

  6. Change in number and type of adverse events [ Time Frame: day 7 ]
    incidence of adverse events and correlation with the therapy


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care or ENT units study the therapeutic process in this obvservational trial in total of 120 patients suffering on respiratory tract infection and/or acute bronchitis
Criteria

Inclusion Criteria:

  • according to instruction for use

Exclusion Criteria:

  • according to instruction for use
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02632851


Locations
Germany
Facharzt für HNO, Allergologie
Cologne, Germany, 50924
Sponsors and Collaborators
Bitop AG
Investigators
Study Chair: R Mösges, Prof Dr University of Cologne
More Information

Publications:
Responsible Party: Bitop AG
ClinicalTrials.gov Identifier: NCT02632851     History of Changes
Other Study ID Numbers: EIL/aBr/2015
First Posted: December 17, 2015    Key Record Dates
Last Update Posted: June 21, 2016
Last Verified: June 2016

Keywords provided by Bitop AG:
inhalation
isotonic saline
NaCl solution 0.9 %
Ectoin
bronchitis
respiratory tract infection

Additional relevant MeSH terms:
Infection
Respiratory Aspiration
Dyspnea
Respiratory Tract Infections
Bronchitis
Acute Disease
Respiration Disorders
Respiratory Tract Diseases
Pathologic Processes
Signs and Symptoms, Respiratory
Signs and Symptoms
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Disease Attributes
Pharmaceutical Solutions